Synosia Therapeutics Begins Phase IIa with Potential Parkinson's ... - PharmaLive.com (press release)
Synosia Therapeutics Begins Phase IIa with Potential Parkinson's ... PharmaLive.com ( release), PA - It is the second most common neurodegenerative disorder, after Alzheimer's disease and affects about one per cent of people aged 65-69 years, ... |
Original post: Synosia Therapeutics Begins Phase IIa with Potential Parkinson's ... - PharmaLive.com (press release) by ©2008 Google at alzheimers treatment - Google News
Blog tag: Alzheimers treatment
Technorati tag: Alzheimers treatment